Self-management of Post COVID-19 Syndrome Using Wearable Biometric Technology

Sponsor
University of Manitoba (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05507190
Collaborator
(none)
20
1
15.9

Study Details

Study Description

Brief Summary

The main objective of this pilot study is to evaluate the impact of a self-management intervention using wearable biometric technology on post-COVID-19 syndrome. In addition, this pilot-study will provide information regarding validity, feasibility, patient compliance and satisfaction, valuable for the design of a future large-scale study.

Condition or Disease Intervention/Treatment Phase
  • Other: Self-management of post COVID-19 respiratory outcomes
N/A

Detailed Description

This pilot-study uses a one-group before-after design. Subjects: a convenience sample of 20 adults 18 years and older in the Winnipeg Health Region with a post-COVID-19 infection (≥ 3 months since acute infection) complaining of mild to severe persistent respiratory symptoms. Intervention: using the participants' initial assessment, personal characteristics, main complaints/needs and goals, the therapist will adjust the exercise plan and personalize the recommendations (e.g. maximum heart rate) as well as instruct the patients about safety precautions (how to pace themselves, when to seek professional or emergency care). Participants will be encouraged to wear the smart shirt as much as they want during the 6 weeks (29), but at a minimum of 1-hour a day (M-F) including while performing the recommended exercises (30-45 min/3 times a week). They should self-monitor their biometric values trying to reach/stay within the target values while wearing the shirt using Hexoskin app installed on an iPad provided by the research team or on the participants' personal device if preferred. Patients will also complete an online survey reporting symptoms intensity and activities completed, 3 times a week (over 6 weeks). Participants would be able to contact the research assistant overseeing the intervention at any time of the study if they have questions or concerns (text message or email). Otherwise, they will receive a follow-up phone call every week or if a significant change in their biometrical data is identified.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
20 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Self-management of Post COVID-19 Syndrome Using Wearable Biometric Technology
Anticipated Study Start Date :
Sep 1, 2022
Anticipated Primary Completion Date :
Jul 30, 2023
Anticipated Study Completion Date :
Dec 30, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: One arm

Self-management group. This pilot-study uses a one-group before-after design.

Other: Self-management of post COVID-19 respiratory outcomes
Intervention: using the participants' initial assessment, personal characteristics, main complaints/needs and goals, the therapist will adjust the exercise plan and personalize the recommendations (e.g. maximum heart rate) as well as instruct the patients about safety precautions (how to pace themselves, when to seek professional or emergency care). Participants will be encouraged to wear the smart shirt as much as they want during the 6 weeks (29), but at a minimum of 1-hour a day (M-F) including while performing the recommended exercises (30-45 min/3 times a week). They should self-monitor their biometric values trying to reach/stay within the target values while wearing the shirt using Hexoskin app installed on an iPad provided by the research team or on the participants' personal device if preferred.

Outcome Measures

Primary Outcome Measures

  1. Change in lung capacity [6 weeks]

    It will be assessed using a SpiroBank Smart F/V multi parameter spirometer (MIR) at pre-post intervention and once a week in between to monitor changes. This portable spirometer, which is MDSAP approved and complaint with ATS/ERS guidelines, connects automatically via Bluetooth to an iOS & Android compatible App (MIR Spirobank). It provides real time feedback through messages and animation on smartphone, to improve personal compliance during the test. The app can generate test results PDF printout with information regarding 19 parameters of lung capacity.

  2. Change in dyspnea [6 weeks]

    Modified Borg Scale (0 "best" to 10 "worse dyspnea") will be used to assess dyspnea.

  3. Change in fatigue [6 weeks]

    Fatigue severity scale (0 -7 "more fatigue") will be used to measure the severity of fatigue.

  4. Chronic fatigue syndrome [6 weeks]

    DePaul Symptoms Questionnaire short form (DSQ-SF) (0 "not present" - 4 "very severe")

  5. Health-related quality of life [6 weeks]

    EuroQol five-dimensional questionnaire (0 "worse health" to 100 "best health")

  6. Postural orthostatic hypotension [6 weeks]

    Orthostatic Stress Test (Postural transitions)

  7. Exercise capacity [6 weeks]

    The 6-min walk test (6 MWT) and the one-minute sit-to-stand test

Secondary Outcome Measures

  1. Symptoms change [6 weeks]

    Participants will be ask to rate their symptoms from 0-10 using an online form (base on the baseline symptoms)

  2. Patient satisfaction with the study [6 week]

    Participants will complete a short summary with questions regarding their satisfaction with the study

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Post-COVID-19 ≥ 3 months after infection.

  • Mild to severe persistent respiratory symptoms

  • Access to a home internet

Exclusion Criteria:
  • History of neurological disease or mental illness

  • Inability to ambulate independently without supervision

  • Inability to complete basic tasks on a smart phone or tablet

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • University of Manitoba

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Diana C Sanchez-Ramirez, PhD, Assistant professor, University of Manitoba
ClinicalTrials.gov Identifier:
NCT05507190
Other Study ID Numbers:
  • HS25512(B2020:042
First Posted:
Aug 18, 2022
Last Update Posted:
Aug 18, 2022
Last Verified:
Aug 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Diana C Sanchez-Ramirez, PhD, Assistant professor, University of Manitoba
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 18, 2022